About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker GKOS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 30, 2026iDose TR Administration in an Office-Based Surgery Setting
NCT07816692 · Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
iDose TR (travoprost intracameral implant) 75 µg
GKOS
Glaukos Corporation
—Recruiting30Mar 2027Registry ↗
Sep 17, 2026Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral…
NCT07075718 · Glaucoma
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.…
GKOS
Glaukos Corporation
Phase 2Recruiting110Mar 2028Registry ↗
Jun 5, 2026Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for K…
NCT07629557 · Keratoconus
Riboflavin Ophthalmic Solutions, UV-A Irradiation System
GKOS
Glaukos Corporation
Phase 4Recruiting15Sep 2027Registry ↗
Jun 2, 2026Travoprost Intraocular Implant + iStent Infinite
NCT06066645 · Glaucoma, Open-Angle
Travoprost Intraocular Implant, iStent infinite
GKOS
Glaukos Corporation
Phase 4Recruiting150May 2027Registry ↗
Mar 30, 2026Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
NCT07495852 · Glaucoma
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.…
GKOS
Glaukos Corporation
Phase 3Recruiting510Jun 2028Registry ↗
Feb 27, 2026Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
NCT07400965 · Demodex Blepharitis
GLK-321 low dose BID, GLK-321 mid dose BID
GKOS
Glaukos Corporation
Phase 2Recruiting250Sep 2026Registry ↗
Feb 27, 2026Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
NCT07400926 · Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Travoprost
GKOS
Glaukos Corporation
—Recruiting30Jun 2026Registry ↗
Feb 10, 2026Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subj…
NCT07400952 · Keratoconus
GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution
GKOS
Glaukos Corporation
Phase 2Recruiting100Apr 2027Registry ↗
Jan 21, 2026Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
NCT06848946 · Glaucoma, Open-angle, Ocular Hypertension (OHT)
iDose TR (travoprost intracameral implant) 75 µg in conjunc…
GKOS
Glaukos Corporation
Phase 4Recruiting132Aug 2026Registry ↗
Jul 24, 2025A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects Wit…
NCT05966493 · Persistent Corneal Epithelial Defect
lufepirsen high dose, Vehicle
GKOS
Glaukos Corporation
Phase 2Recruiting84Dec 2025Registry ↗
Jul 14, 2025NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
NCT04081103 · Corneal Persistent Epithelial Defect
Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lu…
GKOS
Glaukos Corporation
Phase 2Terminated35Feb 7, 2022Registry ↗
Nov 29, 2024Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
NCT03868124 · Glaucoma, Open-Angle, Ocular Hypertension
G2-TR intraocular implant containing travoprost, Sham surge…
GKOS
Glaukos Corporation
Phase 3Completed560Jun 10, 2022Registry ↗
Nov 29, 2024Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha…
NCT03519386 · Glaucoma, Open-Angle, Ocular Hypertension
G2-TR intraocular implant containing travoprost, Sham surge…
GKOS
Glaukos Corporation
Phase 3Completed590Apr 5, 2022Registry ↗
Oct 15, 2024Performance of the Travoprost Intraocular Implant
NCT06582732 · Glaucoma, Open-Angle, Ocular Hypertension
Travoprost Intracameral Implant exchanged at Month 12, Trav…
GKOS
Glaukos Corporation
Phase 2Completed210Nov 2, 2023Registry ↗
Aug 15, 2024Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
NCT05127551 · Glaucoma, Glaucoma, Open-Angle
iStent Infinite, Competitor Device
GKOS
Glaukos Corporation
Not applicableUnknown179Feb 29, 2024Registry ↗
Jul 8, 2024Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
NCT05314738 · Progressive Keratoconus
NXL Energy 1, NXL Energy 2
GKOS
Glaukos Corporation
Phase 1/2Unknown150Aug 2025Registry ↗
Jun 3, 2024Travoprost Intraocular Implant in Conjunction With Cataract Surgery
NCT06061718 · Open Angle Glaucoma, Ocular Hypertension
iDose TR
GKOS
Glaukos Corporation
Phase 3Unknown60Mar 18, 2024Registry ↗
Feb 23, 2024iStent Inject New Enrollment Post-Approval Study
NCT04624698 · Glaucoma, Open-Angle, Glaucoma
iStent Inject Implantation
GKOS
Glaukos Corporation
Not applicableUnknown358May 2026Registry ↗
Feb 23, 2024Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia A…
NCT03319082 · Corneal Ectasia
Corneal Collagen Cross-linking
GKOS
Glaukos Corporation
—Unknown200Feb 2026Registry ↗
Jan 30, 2024Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive…
NCT03442751 · Progressive Keratoconus
Test Article A, Test Article B
GKOS
Glaukos Corporation
Phase 3Completed201Nov 1, 2019Registry ↗
Dec 6, 2023Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
NCT06152861 · Open Angle Glaucoma, Ocular Hypertension
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Op…
GKOS
Glaukos Corporation
Phase 2Unknown250Aug 2024Registry ↗
Sep 28, 2023Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary O…
NCT06057051 · Glaucoma
iStent Infinite
GKOS
Glaukos Corporation
Not applicableRecruiting245Aug 2025Registry ↗
Sep 26, 2023Study of Exchange of Travoprost Intraocular Implant
NCT04615403 · Open Angle Glaucoma
Travoprost
GKOS
Glaukos Corporation
Phase 2Completed33Feb 28, 2022Registry ↗
Sep 26, 2023Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
NCT02754596 · Glaucoma Open-angle
Travoprost Intraocular Implant, high elution, Travoprost In…
GKOS
Glaukos Corporation
Phase 2Completed154Aug 1, 2017Registry ↗
Sep 1, 2023Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
NCT05124275 · Presbyopia
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine O…
GKOS
Glaukos Corporation
Phase 2Completed123Sep 6, 2022Registry ↗
Jul 12, 2023Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
NCT05119920 · Dry Eye Disease, Kerato Conjunctivitis Sicca
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine O…
GKOS
Glaukos Corporation
Phase 2Completed226Jul 27, 2022Registry ↗
Dec 22, 2022Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty
NCT02327312 · Primary Open-Angle Glaucoma
Stents, Laser
GKOS
Glaukos Corporation
Not applicableTerminated91May 31, 2019Registry ↗
Sep 9, 2022iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
NCT03478293 · Primary Open Angle Glaucoma (POAG)
iStent inject surgery
GKOS
Glaukos Corporation
Not applicableTerminated6Dec 30, 2020Registry ↗
Sep 9, 2022A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iS…
NCT03255798 · Glaucoma, Open-Angle
G2 and G3
GKOS
Glaukos Corporation
Not applicableTerminated7Jun 6, 2019Registry ↗
Sep 9, 2022Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iS…
NCT03255785 · Glaucoma, Open-Angle
Cataract surgery plus one iStent and one iStent Supra impla…
GKOS
Glaukos Corporation
Not applicableCompleted15Dec 3, 2019Registry ↗
Sep 8, 2022Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive…
NCT02868190 · Open Angle Glaucoma
Two trabecular micro-bypass stents (iStent inject)
GKOS
Glaukos Corporation
Phase 4Completed57Nov 8, 2019Registry ↗
Sep 8, 2022Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medi…
NCT01444040 · Open-angle Glaucoma
iStent inject, Travoprost
GKOS
Glaukos Corporation
Phase 4Completed196Mar 28, 2019Registry ↗
Sep 7, 2022Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hyp…
NCT02873806 · Open-angle Glaucoma
Implantation of two iStent inject micro-bypass stents, Topi…
GKOS
Glaukos Corporation
Phase 4Completed53Nov 8, 2019Registry ↗
Sep 7, 2022Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoro…
NCT01456390 · Open-Angle Glaucoma
iStent and iStent supra
GKOS
Glaukos Corporation
Not applicableCompleted79Mar 26, 2019Registry ↗
Sep 7, 2022A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Tre…
NCT01252914 · Subject With Primary Open-angle Glaucoma (POAG)
iStent Supra Stent
GKOS
Glaukos Corporation
Phase 4Completed80Dec 16, 2019Registry ↗
Sep 7, 2022Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treate…
NCT01252888 · Subjects With Primary Open-angle Glaucoma (POAG)
iStents
GKOS
Glaukos Corporation
Phase 4Completed39Jul 2016Registry ↗
Aug 31, 2022One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
NCT01517477 · Primary Open Angle Glaucoma (POAG)
iStent, iStent
GKOS
Glaukos Corporation
Not applicableCompleted119Oct 18, 2019Registry ↗
Aug 31, 2022Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One…
NCT01455467 · Open-angle Glaucoma
One iStent, Two iStent
GKOS
Glaukos Corporation
Not applicableCompleted79Oct 18, 2019Registry ↗
Aug 31, 2022Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two…
NCT01444105 · Open-angle Glaucoma
iStent, SLT
GKOS
Glaukos Corporation
Not applicableCompleted80Apr 9, 2019Registry ↗
Aug 31, 2022Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the…
NCT01252849 · Primary Open Angle Glaucoma (POAG)
iStent, iStent
GKOS
Glaukos Corporation
Not applicableCompleted119Oct 8, 2019Registry ↗
May 19, 2022Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injec…
NCT01461291 · Primary Open-angle Glaucoma
iStent inject, Cataract surgery
GKOS
Glaukos Corporation
Not applicableCompleted505Aug 4, 2017Registry ↗
May 19, 2022Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Catarac…
NCT01461278 · Primary Open-angle Glaucoma
iStent supra, Cataract surgery
GKOS
Glaukos Corporation
Not applicableCompleted505Mar 13, 2019Registry ↗
Oct 20, 2021iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study
NCT04624685 · Glaucoma, Open-Angle
GKOS
Glaukos Corporation
—Unknown475Jan 20, 2021Registry ↗
Oct 20, 2021Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Con…
NCT01841450 · Primary Open Angle Glaucoma
iStent, Cataract surgery
GKOS
Glaukos Corporation
Not applicableUnknown360Aug 2021Registry ↗
Apr 26, 2021Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01972854 · Keratoconus
riboflavin solution, placebo solution
GKOS
Glaukos Corporation
Phase 3Terminated92Mar 2016Registry ↗
Apr 26, 2021Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia an…
NCT01893359 · Hyperopia, Hyperopic Astigmatism
riboflavin ophthalmic solution, 0% dextran, UVA Irradiation…
GKOS
Glaukos Corporation
Phase 1/2Terminated2Feb 2015Registry ↗
Apr 26, 2021Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Ref…
NCT01643252 · Corneal Ectasia
riboflavin: 0.12% riboflavin ophthalmic solution with the K…
GKOS
Glaukos Corporation
Phase 3Withdrawn0—Registry ↗
Apr 26, 2021Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01643226 · Keratoconus
riboflavin solution, placebo solution
GKOS
Glaukos Corporation
Phase 3Completed230Jul 2015Registry ↗
Apr 26, 2021Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01344187 · Keratoconus
riboflavin solution, placebo solution
GKOS
Glaukos Corporation
Phase 3Completed236Jun 2015Registry ↗
Apr 26, 2021Feasibility Study of the Vedera KXS for Treatment of Keratoconus
NCT01069848 · Keratoconus
Vedera KXS
GKOS
Glaukos Corporation
Not applicableCompleted23Mar 2011Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:54 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances